0%
Print report
Variant interpretation report

WFS1 c.2452C>T, p.Arg818Cys

NM_006005.3:c.2452C>T NP_005996.2:p.(Arg818Cys) Missense · exon 8 View identifiers
Classification
Uncertain significance

Variant description:

The WFS1 NM_006005.3:c.2452C>T (NP_005996.2:p.(Arg818Cys)) missense variant has previously been reported in somatic cancers (COSMIC; COSV99901749, n = 1 time). Based on available guidelines, this variant is considered to be a Variant of Uncertain Significance (VUS).

Five-step scale from benign to pathogenic. This variant is uncertain. Select a step to read what it means.

Uncertain.The recorded classification is uncertain significance.

In plain language

Gene-level background from the recorded interpretation.

About WFS1

WFS1 encodes wolframin, a transmembrane protein found mainly in the endoplasmic reticulum and involved in the function of cells such as pancreatic beta cells and neurons. Changes in WFS1 can cause Wolfram syndrome, an inherited disorder characterized by diabetes mellitus, optic atrophy, hearing loss, and other neurological problems, as well as autosomal dominant nonsyndromic deafness. WFS1 has no established role in cancer.

LYFE Sciences is an AI system, and it can make mistakes. Criteria may be applied incorrectly, sources may be misread, and a confident-looking classification can still be wrong. Double-check every criterion and its underlying evidence before relying on any call.
01The reasoning

How it was classified

The recorded framework is Generic ACMG/AMP 2015 with ClinGen SVI recommendations. The criteria and strengths shown below come from the saved assessment; this page does not recalculate the classification.

Recorded applied criteria

The applied criteria and their strengths are shown as assessed under the stated framework.

Pathogenic evidence criteria: 1 Benign evidence criteria: 0
Pathogenic criteria applied · 1
PP3Supporting
PP3 · supporting

Met at supporting strength: missense REVEL 0.758 meets the generic PP3 supporting threshold of >=0.644.

Benign criteria applied · 0

No benign criterion marked as applied in the recorded assessment.

Recorded classification: Uncertain significance

VUS: PP3 (supporting) was the only applied criterion, and generic ACMG/AMP fallback rules do not satisfy any pathogenic or benign combination.

02The sources

Evidence at a glance

Evidence summaries and captured source records, where available. Missing entries should not be interpreted as negative findings.

gnomAD v4.1
gnomAD v2.1
Population frequency
8,135 / 1,605,064 alleles

gnomAD v4.1: 8,135 / 1,605,064 alleles. Recorded AF 0.00506833. Recorded homozygote count 35.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 0.00485695; MAF= 0.48569%, 1354/278776 alleles, homozygotes = 9) and has highest observed frequency in the Ashkenazi Jewish population (AF= 0.0281843; MAF= 2.81843%, 285/10112 alleles, homozygotes = 3); grpmax FAF= 0.00677102.

gnomAD-Canada

Not available in gnomAD-Canada v1.0.

No screenshot for this evidence
REVEL score
0.758 recorded score

Recorded REVEL score: 0.758. Refer to the recorded PP3/BP4 rationale for interpretation.

ClinVar submissions
16 reported laboratory submissions

9 Likely benign · 6 Benign · 1 Likely Benign. ClinVar API review status: criteria provided, conflicting classifications.

Context only ClinVar ↗
No screenshot for this evidence
Functional evidence
Not recorded

No standalone functional evidence summary is recorded in evidence_summary.functional.

No listed criterion applied OncoKB ↗
COSMIC
Cancer Hotspots
Somatic evidence
1 recorded samples

This variant has previously been reported in somatic cancers (COSMIC; COSV99901749, n = 1 times).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.

For specialists

Technical detail

ACMG/AMP criteria under Generic ACMG/AMP 2015 with ClinGen SVI recommendations, with the data and sources behind each one.

28 criteria with recorded statuses: 1 met · 11 not met · 12 not assessed · 4 not applicable. Open any row for the full reasoning, the rule and the evidence behind it.

Met Not met Not assessed Not applicable

PS4 is not met because the verified case-control direction is not enriched in affected patients and the reported counts do not meet the generic OR >5.0 requirement.

PP4 and BP5 are not assessed because patient-specific phenotype specificity and an alternate molecular basis are not sufficiently documented.

PP5 and BP6 are not met because the exact variant has no ClinVar expert-panel classification; ordinary laboratory submissions do not trigger either criterion.

Met · 1

PP3 SupportingACMGMet at supporting strength: missense REVEL 0.758 meets the generic PP3 supporting threshold of >=0.644. Details ▾Hide ▴
Reasoning

The variant is a missense substitution, NP_005996.2:p.(Arg818Cys), so the governing generic rule requires the missense REVEL path only; SpliceAI is not used for PP3/BP4 in this situation. REVEL is 0.758, meeting the supplied ClinGen SVI supporting PP3 threshold of >= 0.644 (Pejaver et al. 2022, PMID:36413997). BayesDel is not used because no generic ACMG-strength calibration is established.

Rule
Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.).
Evidence considered
  • Variant consequence: missense, NP_005996.2:p.(Arg818Cys); therefore the generic missense REVEL path applies and the SpliceAI score is not counted for PP3.
  • Local REVEL lookup: score 0.758 for NM_006005.3:c.2452C>T.
  • ClinGen SVI REVEL calibration (Pejaver et al. 2022, PMID:36413997): generic PP3 supporting threshold >= 0.644; REVEL 0.758 meets it.
  • BayesDel score 0.388109 was not used because the supplied generic rules establish no ACMG-strength calibration for BayesDel.
Sources
revel

Not met · 11 · evaluated, threshold not reached

PS1 ACMG_2015Not met: p.Arg818Cys is reported in one patient, but no previously established pathogenic same-amino-acid change is documented. Details ▾Hide ▴
Reasoning

The variant is NP_005996.2:p.(Arg818Cys), but the reviewed evidence does not establish a previously pathogenic variant producing the same amino-acid change by another nucleotide change. PMID:26025012 lists p.Arg818Cys in one genetically confirmed Wolfram syndrome participant, without variant-specific phenotype, segregation, or functional evidence; this is not a previously established pathogenic classification.

Rule
Same amino acid change as a previously established pathogenic variant regardless of nucleotide change.
Evidence considered
  • PMID:26025012, Table 2 lists c.2452C>T, p.Arg818Cys in one genetically confirmed Wolfram syndrome participant, but reports no variant-specific pathogenic evidence.
  • No alternate nucleotide change producing p.Arg818Cys with an established pathogenic interpretation was identified in the reviewed evidence.
Sources
PS4 ACMG_2015Not met: R818C was absent from 152 second-stage patients but present in one control, showing no affected-case enrichment and failing the PS4 OR >5.0 requirement. Details ▾Hide ▴
Reasoning

Generic ACMG/AMP PS4 requires significant enrichment in affected individuals, with OR or RR >5.0 and a confidence interval that excludes 1. The verified R818C report found the variant in 1 of 43 affective-disorder patients in an initial screen, but in the second-stage analysis it was absent from 152 psychiatric patients and present in one control subject. This is not an enrichment pattern for cases. A valid OR and 95% CI cannot be computed from the reported second-stage data because the total number of controls is not reported; regardless, the observed case/control direction is opposite to PS4 enrichment. The literature_pass packet contained no ai_classified_papers requiring additional PS4 verification.

Rule
The prevalence of the variant in affected individuals is significantly increased compared to the prevalence in controls. ... Relative risk (RR) or odds ratio (OR), as obtained from case-control studies, is >5.0 and the confidence interval around the estimate of RR or OR does not include 1.0.
Evidence considered
  • PMID:12605098 abstract/Results: R818C was present in 1 of 43 patients in the initial affective-disorder screen, then absent from 152 psychiatric patients and present in one control subject; this does not show case enrichment.
  • The reported second-stage control denominator is missing, so no valid OR or 95% CI was calculated; the observed direction is nevertheless opposite to PS4 enrichment.
  • literature_pass.json ai_classified_papers was empty; no pre-classified PS4 paper required additional verification.
Still missing
  • The second-stage paper does not report the total control denominator, so a valid OR and 95% CI cannot be calculated from those counts.
Sources
PM1 ACMG_2015Not met: residue 818 has no documented critical-domain evidence or statistically significant hotspot, with Cancer Hotspots returning no result. Details ▾Hide ▴
Reasoning

WFS1 has no VCEP domain table in this case. The generic evidence does not establish that residue 818 lies in a critical and well-established functional domain lacking benign variation, and the Cancer Hotspots query for WFS1 R818 returned no statistically significant hotspot. COSMIC reports one somatic occurrence, but generic ACMG/AMP PM1 requires a supported mutational hotspot or critical functional domain and the single occurrence does not establish either route.

Rule
Located in a mutational hot spot and/or critical and well-established functional domain (e.g. active site of an enzyme) without benign variation.
Evidence considered
  • Cancer Hotspots query WFS1 R818: no statistically significant hotspot and no hotspot row found.
  • COSMIC records one somatic occurrence (COSV99901749), which does not by itself establish a generic ACMG/AMP hotspot.
  • vcep_materials.json contains no WFS1 domain table, so no VCEP-approved critical-domain interval applies.
Sources
PM2 ACMGNot met: gnomAD v4.1 total AF is 0.00506833, far above the generic PM2 supporting threshold of <=0.0001. Details ▾Hide ▴
Reasoning

PM2 is not met. The generic supporting threshold supplied for this case is an allele frequency of <=0.0001. The variant is present in both default all-comers population datasets at substantially higher frequency: gnomAD v4.1 total AF 0.00506833 and gnomAD v2.1 total AF 0.00485695, with grpmax FAF values of 0.00866652 and 0.00677102, respectively. It is therefore not absent or at an extremely low frequency in controls.

Rule
PM2: Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes or Exome Aggregation Consortium....PM2 (supporting): <= 0.0001 — SVI recommendation to downgrade PM2 to Supporting (ClinGen SVI 2020) (PMID:25741868)
Evidence considered
  • gnomAD v4.1 all-comers: AF=0.00506833 from 8135/1605064 alleles; grpmax FAF=0.00866652; homozygotes=35.
  • gnomAD v2.1 all-comers: AF=0.00485695 from 1354/278776 alleles; grpmax FAF=0.00677102; homozygotes=9.
  • Generic calibration threshold supplied for this case: PM2 <=0.0001, with PM2 downgraded to supporting strength under ClinGen SVI guidance (PMID:25741868).
Sources
PM5 ACMG_2015Not met: no different missense variant at residue 818 has been determined pathogenic in the reviewed evidence. Details ▾Hide ▴
Reasoning

The variant is a missense substitution at Arg818, but the reviewed evidence provides no different missense variant at residue 818 that has been determined pathogenic. The same-residue candidate collection contains zero candidates, so the required pathogenic comparator for PM5 is absent.

Rule
Novel missense change at an amino acid residue where a different missense change determined to be pathogenic has been seen before.
Evidence considered
  • The PM5 candidate record reports zero same-residue candidates and zero pathogenic comparator candidates for Arg818.
  • No qualifying pathogenic alternate missense change at Arg818 was found in the reviewed literature and variant evidence.
Sources
pm5_candidatesPMID:25741868 ↗
PP5 ACMG_2015Not met: ClinVar has zero expert-panel submissions for exact R818C, and the available laboratory classifications are not pathogenic or likely pathogenic expert-panel evidence. Details ▾Hide ▴
Reasoning

Generic PP5 is restricted here to an exact-variant ClinVar expert-panel classification of pathogenic or likely pathogenic. ClinVar variation 130748 has zero expert-panel submissions and contains only laboratory submissions with conflicting classifications, predominantly benign or likely benign; therefore PP5 is not met.

Rule
Reputable source recently reports variant as pathogenic, but the evidence is not available to the laboratory to perform an independent evaluation.
Evidence considered
  • ClinVar variation 130748 exact match: expert_panels is empty; review status is criteria provided, conflicting classifications, with laboratory submissions reported as benign or likely benign and one uncertain significance submission.
  • Ordinary laboratory submissions and aggregate ClinVar labels were not used to trigger PP5.
Sources
BA1 ACMGNot met: gnomAD v4.1 grpmax FAF is 0.00866652, below the generic BA1 threshold of 0.05 despite the higher Ashkenazi Jewish point estimate. Details ▾Hide ▴
Reasoning

BA1 is not met. Under the generic default, BA1 requires an allele frequency of at least 0.05. The highest applicable gnomAD filtering allele frequency is the gnomAD v4.1 grpmax FAF of 0.00866652, well below 0.05; the gnomAD v2.1 grpmax FAF is also lower at 0.00677102. The Ashkenazi Jewish point estimate of 0.0281163 is not used to satisfy BA1 because the governing frequency rule requires the filtering allele frequency, not the popmax point estimate. The observed frequency therefore does not support a stand-alone benign call by BA1.

Rule
BA1 (stand-alone): >= 0.05 — ACMG/AMP 2015 stand-alone benign allele frequency (PMID:25741868)...Which frequency figure to use for BS1 and BA1 (ClinGen SVI, Ghosh et al. 2018, PMID 30311383): use the FILTERING allele frequency - the grpmax FAF reported in the gnomAD evidence ('grpmax FAF=') - and never the popmax point estimate.
Evidence considered
  • gnomAD v4.1 all-comers: total AF 0.00506833 from 8135/1605064 alleles; grpmax FAF=0.00866652; Ashkenazi Jewish point estimate AF=0.0281163 from 826/29378 alleles.
  • gnomAD v2.1 all-comers: total AF 0.00485695 from 1354/278776 alleles; grpmax FAF=0.00677102; Ashkenazi Jewish point estimate AF=0.0281843 from 285/10112 alleles.
  • Generic calibration threshold supplied for this case: BA1 >= 0.05 under ACMG/AMP 2015 (PMID:25741868).
Sources
BS1 ACMGNot met: gnomAD v4.1 grpmax FAF is 0.00866652, below the generic BS1 threshold of 0.01; the Ashkenazi Jewish point estimate is not the permitted metric. Details ▾Hide ▴
Reasoning

BS1 is not met on the available population-frequency evidence. The generic BS1 default is >=0.01, and the maximum applicable filtering frequency is the gnomAD v4.1 grpmax FAF of 0.00866652, below that threshold; gnomAD v2.1 is lower at 0.00677102. Although the Ashkenazi Jewish point estimate is 0.0281163, it is not the required filtering allele frequency. WFS1-related Wolfram syndrome is autosomal recessive, but no disease prevalence, penetrance, allelic heterogeneity, or validated maximum-credible-frequency calculation is supplied that would justify replacing the generic threshold. Thus the frequency does not meet BS1.

Rule
BS1: Allele frequency is greater than expected for the disorder....BS1 (strong): >= 0.01 — Generic SVI default; per-gene derivation preferred (Whiffin et al. 2017) (PMID:28518168)...Which frequency figure to use for BS1 and BA1 (ClinGen SVI, Ghosh et al. 2018, PMID 30311383): use the FILTERING allele frequency - the grpmax FAF reported in the gnomAD evidence ('grpmax FAF=') - and never the popmax point estimate.
Evidence considered
  • gnomAD v4.1 all-comers: grpmax FAF=0.00866652; the highest point estimate is Ashkenazi Jewish AF=0.0281163 from 826/29378 alleles.
  • gnomAD v2.1 all-comers: grpmax FAF=0.00677102; the highest point estimate is Ashkenazi Jewish AF=0.0281843 from 285/10112 alleles.
  • Generic calibration threshold supplied for this case: BS1 >= 0.01; maximum-credible-frequency considerations are governed by Whiffin et al. 2017 (PMID:28518168).
Sources
BP1 ACMG_2015Not met: reported WFS1 variants include 156/309 missense versus 111/309 frameshift or nonsense variants, not primarily truncating disease variation. Details ▾Hide ▴
Reasoning

The available WFS1 locus-specific database does not show that disease is caused primarily by truncating variants: it reports 156/309 missense variants (50.5%), compared with 60/309 frameshift variants (19.4%) and 51/309 nonsense variants (16.5%). Thus truncating variants are not the predominant reported disease-associated class in this evidence.

Rule
Missense variant in a gene for which primarily truncating variants are known to cause disease.
Evidence considered
  • Astuti et al. 2017, WFS1 database row: 156/309 missense variants, 60/309 frameshifts, and 51/309 nonsense changes; truncating classes together total 111/309.
  • The reported WFS1 variant spectrum is not primarily truncating by the cited counts.
Sources
BP4 ACMGNot met: missense REVEL 0.758 exceeds the most permissive generic BP4 threshold of <=0.29. Details ▾Hide ▴
Reasoning

The variant is a missense substitution, NP_005996.2:p.(Arg818Cys), so the governing generic rule requires the missense REVEL path only; the SpliceAI score is not used for BP4 in this situation. REVEL is 0.758, which is above the most permissive supplied BP4 threshold of <= 0.29 and therefore does not support BP4. The REVEL result is not a benign gray-zone result that permits substitution of SpliceAI, and BayesDel is not used because no generic ACMG-strength calibration is established.

Rule
Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc)
Evidence considered
  • Variant consequence: missense, NP_005996.2:p.(Arg818Cys); therefore the generic missense REVEL path applies and the SpliceAI score is not counted for BP4.
  • Local REVEL lookup: score 0.758 for NM_006005.3:c.2452C>T.
  • ClinGen SVI REVEL calibration (Pejaver et al. 2022, PMID:36413997): generic BP4 supporting threshold <= 0.29; REVEL 0.758 does not meet it.
  • BayesDel score 0.388109 was not used because the supplied generic rules establish no ACMG-strength calibration for BayesDel.
Sources
revel
BP6 ACMG_2015Not met: exact R818C has no ClinVar expert-panel classification, so ordinary benign or likely benign laboratory submissions cannot trigger BP6. Details ▾Hide ▴
Reasoning

Generic BP6 is restricted here to an exact-variant ClinVar expert-panel classification of benign or likely benign. ClinVar variation 130748 has zero expert-panel submissions; its benign and likely benign assertions are ordinary laboratory submissions and cannot trigger BP6 under the specified rule.

Rule
Reputable source recently reports variant as benign, but the evidence is not available to the laboratory to perform an independent evaluation.
Evidence considered
  • ClinVar variation 130748 exact match: expert_panels is empty; benign and likely benign classifications come from individual laboratory submissions.
  • Ordinary laboratory submissions and the aggregate ClinVar label were not used to trigger BP6.
Sources

Not assessed · 12 · no assessment recorded

PS2 ACMG_2015Not assessed: no parental genotypes, maternity/paternity confirmation, or family-history data are reported for c.2452C>T (p.Arg818Cys). Details ▾Hide ▴
Reasoning

No case-specific evidence documents that NM_006005.3:c.2452C>T (p.Arg818Cys) occurred de novo, that both maternity and paternity were confirmed, that the proband had the relevant disease, or that there was no family history. PMID:26025012 lists the variant in one genetically confirmed Wolfram syndrome participant but explicitly reports no variant-specific segregation data.

Rule
De novo (both maternity and paternity confirmed) in a patient with the disease and no family history.
Evidence considered
  • The case evidence identifies no parental testing, maternity/paternity confirmation, or family-history assessment for NM_006005.3:c.2452C>T (NP_005996.2:p.(Arg818Cys)).
  • PMID:26025012, Table 2, lists c.2452C>T, p.Arg818Cys in one participant but reports no variant-specific segregation data.
Still missing
  • Proband phenotype and disease diagnosis linked to this variant
  • Maternal genotype and maternity confirmation
  • Paternal genotype and paternity confirmation
  • Family history and de novo status
Sources
PS3 ACMG_2015Not assessed: no variant-specific validated functional assay, assay control, or reproducible laboratory result is reported for WFS1 p.Arg818Cys. Details ▾Hide ▴
Reasoning

The variant-specific literature reviewed identifies WFS1 c.2452C>T (p.Arg818Cys) in clinical cohorts or databases but does not report a validated in vitro or in vivo functional assay, assay controls, reproducibility, or a measured damaging effect on the WFS1 gene product. Clinical observation, database inclusion, and genotype-phenotype summaries are not functional-study evidence. Therefore PS3 cannot be assessed from the available evidence.

Rule
PS3: Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product.
Evidence considered
  • PMID:26025012, Table 2 lists c.2452C>T, p.Arg818Cys in one genetically confirmed Wolfram syndrome participant, but the study reports cohort-level clinical assessments and no variant-specific functional assay.
  • PMID:28432734 describes the WFS1 variant database and genotype classification, but does not report a variant-specific functional assay for p.Arg818Cys.
  • PMID:12605098 reports R818C in psychiatric cases and a control subject, but provides no functional assay or measured WFS1 protein effect.
Still missing
  • A variant-specific in vitro or in vivo assay measuring WFS1 protein function or relevant biological activity is needed.
  • Assay controls, validation, and reproducibility data are not available.
Sources
PM3 ACMG_2015Not assessed: the variant was reported with p.Gly780Ala, but no parental testing or other evidence establishes trans phase or pathogenicity of the partner. Details ▾Hide ▴
Reasoning

PM3 cannot be assessed from the available evidence. WFS1 is associated with recessive Wolfram syndrome, and PMID:26025012 reports NM_006005.3:c.2452C>T (p.Arg818Cys) in one genetically confirmed participant together with p.Gly780Ala, but it does not report whether the variants are in trans or cis, parental origin, or whether the second variant is pathogenic. The required phase evidence from parents or offspring is therefore absent.

Rule
For recessive disorders, detected in trans with a pathogenic variant ... This requires testing of parents (or offspring) to determine phase.
Evidence considered
  • PMID:26025012, Table 2: one genetically confirmed Wolfram syndrome participant is listed with c.2339G>C (p.Gly780Ala) and c.2452C>T (p.Arg818Cys), but the table does not provide cis/trans phase, parental origin, or a pathogenicity assertion for p.Gly780Ala.
  • The case summary describes WFS1-related Wolfram syndrome as autosomal recessive, but no case-specific parent or offspring testing establishes phase for this variant pair.
Still missing
  • Parental or offspring testing, or equivalent molecular phasing, is needed to establish whether c.2452C>T is in trans with a pathogenic WFS1 variant.
  • The pathogenic classification of the reported p.Gly780Ala partner is not established in the available evidence.
Sources
PM6 ACMG_2015Not assessed: the variant is reported in one participant, but no parental testing or other de novo evidence is provided. Details ▾Hide ▴
Reasoning

No case-specific evidence documents an assumed de novo occurrence of NM_006005.3:c.2452C>T (p.Arg818Cys). The available variant report lists the variant in one participant but provides no parental genotypes or other evidence establishing de novo status without confirmed maternity and paternity.

Rule
Assumed de novo, but without confirmation of paternity and maternity.
Evidence considered
  • PMID:26025012, Table 2, reports c.2452C>T, p.Arg818Cys in one participant but does not report parental testing or de novo status.
  • No case-specific evidence establishes that the variant was assumed de novo.
Still missing
  • Parental genotypes
  • Evidence that the variant is absent from both parents
  • Documentation supporting assumed de novo status
Sources
PP1 ACMG_2015Not assessed: zero affected-relative meioses or variant-specific co-segregation results are reported for c.2452C>T (p.Arg818Cys). Details ▾Hide ▴
Reasoning

No affected family members, informative meioses, or genotype-phenotype segregation results are reported for NM_006005.3:c.2452C>T (p.Arg818Cys). PMID:26025012 reports the variant in one participant and explicitly provides no variant-specific segregation data, so co-segregation cannot be assessed or strengthened.

Rule
Co-segregation with disease in multiple affected family members in a gene definitively known to cause the disease.
Evidence considered
  • No affected relatives or informative meioses are documented for this variant.
  • PMID:26025012, Table 2, lists the variant in one participant but reports no variant-specific segregation data.
Still missing
  • Pedigree with affected relatives
  • Genotypes and phenotypes of informative relatives
  • Number of affected-relative meioses
  • Variant-specific co-segregation results
Sources
PP2 ACMG_2015Not assessed: WFS1 has 156/309 reported missense variants, but the required low benign-missense rate is not established. Details ▾Hide ▴
Reasoning

The available WFS1 variant database reports 156 missense variants among 309 unique variants, showing that missense variation is common in the observed disease-associated database, but it does not establish the gene's rate of benign missense variation. The available evidence also does not provide a governing quantitative threshold or a validated gene-level benign-missense assessment, so PP2 cannot be assessed without using an unstated threshold.

Rule
Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.
Evidence considered
  • Astuti et al. 2017, WFS1 database variant-type counts: 156/309 missense variants, 60/309 frameshifts, and 51/309 nonsense changes.
  • The source does not quantify the rate of benign WFS1 missense variation or establish a validated PP2 threshold.
Still missing
  • A validated gene-level assessment or governing threshold for WFS1 benign missense variation is unavailable.
Sources
PP4 ACMG_2015Not assessed: the exact-variant report gives no specific patient phenotype or family history demonstrating a single-etiology WFS1 disorder. Details ▾Hide ▴
Reasoning

The generic PP4 rule requires a patient's phenotype or family history to be highly specific for a disease with a single genetic etiology. The available exact-variant report lists R818C in a five-year-old participant with no diagnosis at assessment and provides no patient-specific phenotype or family history that establishes classic Wolfram syndrome or another single-etiology WFS1 disorder. The available evidence is therefore insufficient to assess PP4.

Rule
Patient’s phenotype or family history is highly specific for a disease with a single genetic etiology.
Evidence considered
  • PMID:26025012 Table 2 lists one five-year-old participant carrying p.Gly780Ala and p.Arg818Cys with no diagnosis at the time of assessment; no patient-specific phenotype or phase evidence isolates R818C.
Still missing
  • Patient-level phenotype and family-history details are unavailable for assessing specificity for a single genetic etiology.
Sources
BS2 ACMG_2015Not assessed: gnomAD reports 35 homozygotes, but no individual age or phenotype data confirm healthy adults as required for BS2 in recessive Wolfram syndrome. Details ▾Hide ▴
Reasoning

BS2 cannot be established from the available evidence. gnomAD v4.1 reports 35 homozygotes and gnomAD v2.1 reports 9 homozygotes, which is relevant because classic Wolfram syndrome is described as autosomal recessive. However, the gnomAD records do not identify individual ages, confirm healthy adult status, establish absence of early-onset disease, or provide phenotype adjudication for those homozygotes. A publication reports R818C in one psychiatric-study control subject, but that is not documented as a healthy adult homozygote and does not establish the BS2 requirement for a recessive disorder. Individual-level age and phenotype evidence for homozygous carriers is required before applying BS2.

Rule
BS2: Observed in a healthy adult individual for a recessive (homozygous), dominant (heterozygous), or X-linked (hemizygous) disorder, with full penetrance expected at an early age.
Evidence considered
  • gnomAD v4.1 reports 35 homozygotes overall, including 8 Ashkenazi Jewish homozygotes; gnomAD v2.1 reports 9 homozygotes overall, including 3 Ashkenazi Jewish homozygotes.
  • The gene context identifies classic Wolfram syndrome as autosomal recessive; PMID:11317350 describes Wolfram syndrome as having an autosomal recessive mode of inheritance.
  • PMID:12605098 reports that R818C was present in one control subject, but the source does not establish that the subject was a healthy adult homozygote or that the subject was unaffected by Wolfram syndrome.
Still missing
  • Individual-level age and phenotype information for the reported homozygotes is unavailable.
  • No evidence confirms that the reported homozygotes were healthy adults without early-onset Wolfram syndrome.
  • The control-subject report does not establish homozygosity or healthy-adult status.
Sources
BS3 ACMG_2015Not assessed: no variant-specific validated assay demonstrates preserved WFS1 protein function or splicing for p.Arg818Cys. Details ▾Hide ▴
Reasoning

The variant-specific literature reviewed identifies WFS1 c.2452C>T (p.Arg818Cys) in clinical cohorts or databases but does not report a validated in vitro or in vivo functional assay demonstrating no damaging effect on WFS1 protein function or splicing. Clinical observation, database inclusion, and a control occurrence do not establish a well-established benign functional result. Therefore BS3 cannot be assessed from the available evidence.

Rule
BS3: Well-established in vitro or in vivo functional studies show no damaging effect on protein function or splicing.
Evidence considered
  • PMID:26025012, Table 2 lists c.2452C>T, p.Arg818Cys in one genetically confirmed Wolfram syndrome participant, but the study reports cohort-level clinical assessments and no variant-specific functional assay.
  • PMID:28432734 describes the WFS1 variant database and genotype classification, but does not report a variant-specific functional assay for p.Arg818Cys.
  • PMID:12605098 reports R818C in psychiatric cases and a control subject, but provides no functional assay establishing normal WFS1 function or splicing.
Still missing
  • A variant-specific in vitro or in vivo assay evaluating WFS1 protein function or splicing is needed.
  • Assay controls, validation, and reproducibility data are not available.
Sources
BS4 ACMG_2015Not assessed: no affected family members with documented variant status are available to demonstrate lack of segregation. Details ▾Hide ▴
Reasoning

No affected family members carrying or lacking NM_006005.3:c.2452C>T (p.Arg818Cys) are described, and no pedigree or familial genotype-phenotype comparison is available. Therefore, lack of segregation in affected members cannot be established.

Rule
Lack of segregation in affected members of a family.
Evidence considered
  • No affected relatives with documented genotype and phenotype are reported for this variant.
  • PMID:26025012, Table 2, provides a single participant-level variant listing without familial non-segregation data.
Still missing
  • Affected-family-member pedigree
  • Variant testing in affected relatives
  • Phenotype and genotype comparison sufficient to demonstrate non-segregation
Sources
BP2 ACMG_2015Not assessed: a second variant was reported, but its cis/trans phase and pathogenicity are not established, so BP2's allelic requirement remains unresolved. Details ▾Hide ▴
Reasoning

BP2 cannot be assessed from the available evidence. The exact variant is reported with p.Gly780Ala in one Wolfram syndrome participant, but PMID:26025012 does not establish whether the variants are in cis or trans, and it does not establish p.Gly780Ala as pathogenic. There is also no evidence that the variant is in trans with a pathogenic variant in a fully penetrant dominant WFS1 disorder. The required allelic relationship is therefore unresolved.

Rule
Observed in trans with a pathogenic variant for a fully penetrant dominant gene/disorder or observed in cis with a pathogenic variant in any inheritance pattern.
Evidence considered
  • PMID:26025012, Table 2: c.2452C>T (p.Arg818Cys) and c.2339G>C (p.Gly780Ala) are listed in the same participant, but the report does not establish cis/trans phase or classify p.Gly780Ala as pathogenic.
  • No source reviewed provides a fully penetrant dominant WFS1 case with this variant in trans to a documented pathogenic variant.
Still missing
  • Molecular phasing is needed to determine whether the reported variant pair is in cis or trans.
  • A documented pathogenic classification for the partner variant is needed.
  • For the dominant BP2 path, evidence of a pathogenic variant in trans in a fully penetrant dominant WFS1 disorder is unavailable.
Sources
BP5 ACMG_2015Not assessed: R818C was reported with another WFS1 allele, but no separate molecular diagnosis or alternate disease basis was established. Details ▾Hide ▴
Reasoning

The generic BP5 rule requires the variant to be found in a case with an alternate molecular basis for disease. The available exact-variant paper reports R818C together with another WFS1 missense allele but does not establish phase, a separate molecular diagnosis, or an alternate gene-based cause of the participant's condition. No sufficient evidence establishes the BP5 scenario, so BP5 is not assessed.

Rule
Variant found in a case with an alternate molecular basis for disease.
Evidence considered
  • PMID:26025012 Table 2 reports p.Gly780Ala and p.Arg818Cys in one participant but supplies no phase evidence and no alternate-gene or alternate-molecular diagnosis.
Still missing
  • No confirmed alternate molecular basis, phase information, or separate pathogenic diagnosis is available for the reported case.
Sources
Not applicable · 4· recorded as not applicable Show reasons ▾Hide reasons ▴
PVS1 N/ANot applicable: PVS1 requires a null variant (nonsense, frameshift, canonical splice, start-loss or stop-loss), and this is a missense variant. Details ▾Hide ▴
Reasoning

PVS1 (ClinGen SVI PVS1 recommendations, PMC6185798, pvs1_generic_framework) applies only to null variant classes — nonsense, frameshift, canonical ±1/2 splice-consensus, translation-initiation-codon loss, and stop-loss variants — each expected to trigger nonsense-mediated decay or otherwise abolish normal protein function. NM_006005.3:c.2452C>T in WFS1 is a missense substitution predicted to produce NP_005996.2:p.(Arg818Cys). As a result, no null-variant mechanism (nonsense-mediated decay, truncation, or canonical splice disruption) is triggered by this variant class, so PVS1's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PVS1 for WFS1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_null_variant_class
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
PM4 N/ANot applicable: PM4 requires a protein-length change, and this is a missense variant. Details ▾Hide ▴
Reasoning

PM4 (Richards et al. 2015, PMID:25741868) applies to protein length changes: in-frame insertions/deletions in a non-repetitive region, or stop-loss variants that extend the protein past the reference stop codon. NM_006005.3:c.2452C>T in WFS1 is a missense substitution predicted to produce NP_005996.2:p.(Arg818Cys). As a result, no change in protein length occurs, so there is nothing for this criterion to evaluate, so PM4's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PM4 for WFS1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_stop_loss_or_nonrepeat_indel
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
BP3 N/ANot applicable: BP3 requires an in-frame indel in a repeat region, and this is a missense variant. Details ▾Hide ▴
Reasoning

BP3 (Richards et al. 2015, PMID:25741868) applies to in-frame insertions/deletions located in a repetitive region without a known function. NM_006005.3:c.2452C>T in WFS1 is a missense substitution predicted to produce NP_005996.2:p.(Arg818Cys). As a result, the variant does not alter protein length within a repeat region, so there is nothing for this criterion to evaluate, so BP3's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP3 for WFS1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_repeat_region_indel
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
BP7 N/ANot applicable: BP7 requires a synonymous variant, and this is a missense variant. Details ▾Hide ▴
Reasoning

BP7 (Richards et al. 2015, PMID:25741868) is defined for a synonymous (silent) variant for which splicing prediction algorithms predict no impact to the splice consensus sequence and the nucleotide is not highly conserved. NM_006005.3:c.2452C>T in WFS1 is a missense substitution predicted to produce NP_005996.2:p.(Arg818Cys). As a result, the encoded protein sequence is altered, so the criterion's silent-variant premise does not hold regardless of any splicing prediction, so BP7's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP7 for WFS1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_synonymous
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules

Identifiers

Gene
WFS1
Transcript
NM_006005.3
Coding (HGVS c.)
NM_006005.3:c.2452C>T
Protein (HGVS p.)
NP_005996.2:p.(Arg818Cys)
GRCh38
chr4:6302247 C>T
GRCh37
chr4:6303974 C>T
Location and type
Exon 8 · missense
ClinVar
130748
COSMIC
COSV99901749

Gene diagram

Every interpreted variant in WFS1, mapped onto the exon structure of NM_006005.3. Select a row to find it on the plot.

WFS1NM_006005.3
Fetching transcript structure from UCSC…
gnomAD v4.1 8,135 / 1,605,064 alleles AF 0.00507 · 35 homozygotes · FAF 0.00867
gnomAD v2.1 1,354 / 278,776 alleles AF 0.00486 · 9 homozygotes · FAF 0.00677
gnomAD-Canada v1.0 Allele count data not recorded

By genetic ancestry

gnomAD v4.1

AF 0.0051 · 8135 / 1,605,064 alleles · 35 hom · FAF 0.0087
Ashkenazi Jewish826 / 29,378 0.0288 hom
Middle Eastern65 / 6,038 0.0111 hom
South Asian694 / 90,750 0.00769 hom
Remaining individuals366 / 62,128 0.00591 hom
European (non-Finnish)5911 / 1,174,286 0.00516 hom
European (Finnish)116 / 62,134 0.0019
Admixed American108 / 59,828 0.0018
African/African American47 / 74,904 0.00063
East Asian2 / 44,706 4.5e-05
0 alternate alleles recorded in 1 other group: Amish.

gnomAD v2.1

AF 0.0049 · 1354 / 278,776 alleles · 9 hom · FAF 0.0068
Ashkenazi Jewish285 / 10,112 0.0283 hom
South Asian229 / 30,228 0.00762 hom
European (non-Finnish)682 / 127,248 0.00543 hom
Remaining individuals37 / 7,110 0.00521 hom
European (Finnish)56 / 24,178 0.0023
Admixed American51 / 35,252 0.0014
African/African American13 / 24,820 0.00052
East Asian1 / 19,828 5e-05

Statements

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 0.00506833; MAF= 0.50683%, 8135/1605064 alleles, homozygotes = 35) and has highest observed frequency in the Ashkenazi Jewish population (AF= 0.0281163; MAF= 2.81163%, 826/29378 alleles, homozygotes = 8); grpmax FAF= 0.00866652.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 0.00485695; MAF= 0.48569%, 1354/278776 alleles, homozygotes = 9) and has highest observed frequency in the Ashkenazi Jewish population (AF= 0.0281843; MAF= 2.81843%, 285/10112 alleles, homozygotes = 3); grpmax FAF= 0.00677102.

gnomAD-Canada

Not available in gnomAD-Canada v1.0.

SpliceAI and Pangolin

SpliceAI acceptor lossat +122 bp
0.000
SpliceAI acceptor gainat +108 bp
0.000
SpliceAI donor lossat +424 bp
0.000
SpliceAI donor gainat +226 bp
0.000
Pangolin splice lossmagnitude shown
-0.001
Pangolin splice gain
0.001

Other predictors

REVEL
0.758
BayesDel
0.388

How the predictions were used

PP3 SupportingACMGMet at supporting strength: missense REVEL 0.758 meets the generic PP3 supporting threshold of >=0.644. Details ▾Hide ▴
Reasoning

The variant is a missense substitution, NP_005996.2:p.(Arg818Cys), so the governing generic rule requires the missense REVEL path only; SpliceAI is not used for PP3/BP4 in this situation. REVEL is 0.758, meeting the supplied ClinGen SVI supporting PP3 threshold of >= 0.644 (Pejaver et al. 2022, PMID:36413997). BayesDel is not used because no generic ACMG-strength calibration is established.

Rule
Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.).
Evidence considered
  • Variant consequence: missense, NP_005996.2:p.(Arg818Cys); therefore the generic missense REVEL path applies and the SpliceAI score is not counted for PP3.
  • Local REVEL lookup: score 0.758 for NM_006005.3:c.2452C>T.
  • ClinGen SVI REVEL calibration (Pejaver et al. 2022, PMID:36413997): generic PP3 supporting threshold >= 0.644; REVEL 0.758 meets it.
  • BayesDel score 0.388109 was not used because the supplied generic rules establish no ACMG-strength calibration for BayesDel.
Sources
revel
BP4 ACMGNot met: missense REVEL 0.758 exceeds the most permissive generic BP4 threshold of <=0.29. Details ▾Hide ▴
Reasoning

The variant is a missense substitution, NP_005996.2:p.(Arg818Cys), so the governing generic rule requires the missense REVEL path only; the SpliceAI score is not used for BP4 in this situation. REVEL is 0.758, which is above the most permissive supplied BP4 threshold of <= 0.29 and therefore does not support BP4. The REVEL result is not a benign gray-zone result that permits substitution of SpliceAI, and BayesDel is not used because no generic ACMG-strength calibration is established.

Rule
Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc)
Evidence considered
  • Variant consequence: missense, NP_005996.2:p.(Arg818Cys); therefore the generic missense REVEL path applies and the SpliceAI score is not counted for BP4.
  • Local REVEL lookup: score 0.758 for NM_006005.3:c.2452C>T.
  • ClinGen SVI REVEL calibration (Pejaver et al. 2022, PMID:36413997): generic BP4 supporting threshold <= 0.29; REVEL 0.758 does not meet it.
  • BayesDel score 0.388109 was not used because the supplied generic rules establish no ACMG-strength calibration for BayesDel.
Sources
revel
BP7 N/ANot applicable: BP7 requires a synonymous variant, and this is a missense variant. Details ▾Hide ▴
Reasoning

BP7 (Richards et al. 2015, PMID:25741868) is defined for a synonymous (silent) variant for which splicing prediction algorithms predict no impact to the splice consensus sequence and the nucleotide is not highly conserved. NM_006005.3:c.2452C>T in WFS1 is a missense substitution predicted to produce NP_005996.2:p.(Arg818Cys). As a result, the encoded protein sequence is altered, so the criterion's silent-variant premise does not hold regardless of any splicing prediction, so BP7's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP7 for WFS1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_synonymous
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules

Statement

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.00). REVEL score = 0.758. BayesDel score = 0.388109.

10 paper records listed. No publication is explicitly linked to an applied criterion in the recorded metadata. None of the listed paper records explicitly indicates that the variant is named.

Recorded publications

  • WFS1/wolframin mutations, Wolfram syndrome, and associated diseases.
    Khanim F et al. · 2001
    No paper-specific finding is recorded.
    PMID 11317350 ↗
  • A systematic approach to assessing the clinical significance of genetic variants.
    Duzkale H et al. · 2013
    No paper-specific finding is recorded.
    PMID 24033266 ↗
  • Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
    No paper-specific finding is recorded.
    PMID 25741868 ↗
  • Mutational spectrum of the WFS1 gene in Wolfram syndrome, nonsyndromic hearing impairment, diabetes mellitus, and psychiatric disease.
    Cryns K et al. · 2003
    No paper-specific finding is recorded.
    PMID 12955714 ↗
  • Phenotype-genotype correlations in a series of wolfram syndrome families.
    Smith CJ et al. · 2004
    No paper-specific finding is recorded.
    PMID 15277431 ↗
  • Genetic Hearing Loss Overview.
    Adam MP et al. · 1993
    No paper-specific finding is recorded.
    PMID 20301607 ↗
  • WFS1 Spectrum Disorder.
    Adam MP et al. · 1993
    No paper-specific finding is recorded.
    PMID 20301750 ↗
  • Neurologic features and genotype-phenotype correlation in Wolfram syndrome.
    Chaussenot A et al. · 2011
    No paper-specific finding is recorded.
    PMID 21446023 ↗
  • ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007.
    No paper-specific finding is recorded.
    PMID 18414213 ↗
  • Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.
    No paper-specific finding is recorded.
    PMID 28492532 ↗

Screenshots represent source records captured during evidence collection. Select one to view the recorded source content.

All source links

Statements for reports

The evidence statements recorded by the interpretation pipeline. They have not been reinterpreted by the page.

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 0.00506833; MAF= 0.50683%, 8135/1605064 alleles, homozygotes = 35) and has highest observed frequency in the Ashkenazi Jewish population (AF= 0.0281163; MAF= 2.81163%, 826/29378 alleles, homozygotes = 8); grpmax FAF= 0.00866652.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 0.00485695; MAF= 0.48569%, 1354/278776 alleles, homozygotes = 9) and has highest observed frequency in the Ashkenazi Jewish population (AF= 0.0281843; MAF= 2.81843%, 285/10112 alleles, homozygotes = 3); grpmax FAF= 0.00677102.

gnomAD-Canada

Not available in gnomAD-Canada v1.0.

ClinVar

This variant has been reported in ClinVar as Likely benign (9 clinical laboratories) and as Benign (6 clinical laboratories) and as Likely Benign (1 clinical laboratory). (ClinVarID = 130748)

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.00). REVEL score = 0.758. BayesDel score = 0.388109.

Somatic

This variant does not lie in a statistically significant hotspot. This variant has previously been reported in somatic cancers (COSMIC; COSV99901749, n = 1 times).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.